EMBC vs TMDX: fair value comparison
Embecta Corp. and TransMedics Group, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our ranking by discount to fair value.
| EMBC | TMDX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $6.27 | $70.78 |
| 12-month range | $2.90–$14.64 | $62.04–$150.42 |
| Rank by discount to fair value | #11 of 108 Healthcare | #100 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Low | High |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | High |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: EMBC fair value analysis · TMDX fair value analysis